Published in J Infect Dis on March 22, 2015
The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine (2015) 1.28
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control. Cell (2015) 1.00
Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science (2016) 0.98
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol (2015) 0.92
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Rev Vaccines (2015) 0.87
Recent advances in understanding dengue. F1000Res (2016) 0.82
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis (2016) 0.82
Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg (2016) 0.79
A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate. J Infect Dis (2015) 0.77
The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits. PLoS Med (2016) 0.76
A novel indirect ELISA for diagnosis of dengue fever. Indian J Med Res (2016) 0.75
Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. J Virol (2017) 0.75
Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine (2016) 0.75
Prospects for dengue vaccines for travelers. Clin Exp Vaccine Res (2016) 0.75
Prevention and Control Strategies to Counter Dengue Virus Infection. Front Cell Infect Microbiol (2017) 0.75
The global distribution and burden of dengue. Nature (2013) 27.92
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Dengue. Lancet (2007) 10.54
Dengue. N Engl J Med (2012) 10.45
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis (2012) 5.29
Locally acquired Dengue--Key West, Florida, 2009-2010. MMWR Morb Mortal Wkly Rep (2010) 3.83
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 2.51
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis (2010) 2.45
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis (2010) 1.96
A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg (2001) 1.85
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis (2014) 1.67
Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol (2006) 1.44
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine (2011) 1.36
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin (2006) 1.36
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin (2006) 1.35
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg (2008) 1.28
Antibodies determine virulence in dengue. Ann N Y Acad Sci (2009) 1.11
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg (2009) 1.11
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis (2011) 1.04
Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis (2010) 1.00
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine (2013) 0.94
Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl Trop Dis (2012) 0.90